Constipation is in the main trial table of 8 labels. The highest rate printed is 24% on Foundayo 17.2 mg (9% on placebo) and the lowest 3.1% on Ozempic 1 mg (1.5% on placebo). Separate trials, so not a ranking. Trulicity and Byetta list it only among reports after approval, without a rate.
Read from each manufacturer's FDA label on DailyMed. The newest revision saying anything on this is Aug 28, 2026.
At the highest dose in each label's main table. Separate trials with different people, so compare each rate with its own placebo group, not with another medicine.
| Medicine | Dose | On it | On placebo | Difference | Label |
|---|---|---|---|---|---|
| Foundayo | 17.2 mg | 24% | 9% | +15 points | DailyMed |
| Wegovy | 2.4 mg | 24% | 11% | +13 points | DailyMed |
| Saxenda | 3 mg | 19.4% | 8.5% | +10.9 points | DailyMed |
| Zepbound | 15 mg | 11% | 5% | +6 points | DailyMed |
| Mounjaro | 15 mg | 7% | 1% | +6 points | DailyMed |
| Rybelsus and Ozempic tablets | 14 mg | 5% | 2% | +3 points | DailyMed |
| Victoza | 1.8 mg | 5% | 1% | +4 points | DailyMed |
| Ozempic | 1 mg | 3.1% | 1.5% | +1.6 points | DailyMed |
Sentences from each label's warnings and side effect sections. Only cross-references are removed.
Label revised Jun 18, 2026. DailyMed
Label revised Aug 27, 2026. DailyMed
Label revised Jun 16, 2026. DailyMed
Label revised Feb 25, 2026. DailyMed
Ozempic, Rybelsus and Ozempic tablets, Zepbound, Foundayo, Victoza, Byetta: listed only among reports after approval, which come with no rate because nobody knows how many people took the medicine.
Counts of voluntary reports from patients and doctors. They cannot show that a medicine caused anything and cannot give a rate, and a brand used by more people draws more reports.
| Medicine | Reports naming | All reports on it |
|---|---|---|
| Ozempic | Constipation: 4,639 | 70,863 |
| Mounjaro | Constipation: 3,769 | 97,440 |
| Zepbound | Constipation: 3,740 | 80,835 |
| Trulicity | Constipation: 2,360 | 87,279 |
| Victoza | Constipation: 1,297 | 41,462 |
| Wegovy | Constipation: 1,251 | 25,993 |
| Byetta | Constipation: 1,181 | 52,087 |
| Rybelsus and Ozempic tablets | Constipation: 443 | 7,758 |
| Saxenda | Constipation: 342 | 7,270 |
| Foundayo | Constipation: 331 | 3,050 |
Counted through openFDA from FDA's Adverse Event Reporting System, refreshed weekly. One report can name several terms.
Written from each source's own record as it changes. Every change on GLPcompare
No trial here ranks them. By the rates each label prints, Foundayo 17.2 mg is highest at 24% (placebo 9%) and Ozempic 1 mg lowest at 3.1% (placebo 1.5%). These come from separate trials with different people and doses, so compare each to its own placebo group.
In its FDA label, 24% of people taking Foundayo 17.2 mg reported constipation, against 9% on placebo.
In its FDA label, 24% of people taking Wegovy 2.4 mg reported constipation, against 11% on placebo.
In its FDA label, 19.4% of people taking Saxenda 3 mg reported constipation, against 8.5% on placebo.
In its FDA label, 11% of people taking Zepbound 15 mg reported constipation, against 5% on placebo.
In its FDA label, 7% of people taking Mounjaro 15 mg reported constipation, against 1% on placebo.
In its FDA label, 5% of people taking Rybelsus and Ozempic tablets 14 mg reported constipation, against 2% on placebo.
Trial rates describe groups, not what one person will feel. Talk to your clinician before starting, stopping or changing a medicine.